Roche Holding Ltd. http://www.alacrastore.com/company-snapshot/Roche_Holding_Ltd-1008052 Friday, July 25, 2008 11:20:09 PM 1008052 Roche Holding Ltd. en AlacraStore RSS Builder 1.0 30 CANADA - Roche Holding AG definitively agreed to acquire all the outstanding common stock of Arius Research Inc, a biotechnology company, for #.## Canadian dollars ($#.### US) in cash per share, or a total value of C$###.### mil ($###.### mil). The transaction was subject to customary closing conditions and regulatory approvals.7/24/2008 2:29:22 PM77119M04045477119M040454Roche Holding AGArius Research IncRoche Holding AGArius Research Inchttp://www.alacrastore.com/storecontent/Thomson_M%26A/Roche_Holding_AG_acquires_Arius_Research_Inc-1998030040sdc/19980300401998030040Copyright © 2008, Thomson Financial, All Rights ReservedZurichDrugsSwitzerlandPharmaceutical preparations2834FFForeignPublicROG2833:Medicinal chemicals and botanical products2834:Pharmaceutical preparations2835:In vitro and in vivo diagnostic substances2836:Biological products, except diagnostic substances2869:Industrial organic chemicals, nec2899:Chemicals and chemical preparations, nec3841:Surgical and medical instruments and apparatus6719:Offices of holding companies, nec8731:Commercial physical and biological research2833:Medicinal chemicals and botanical products2834:Pharmaceutical preparations2835:In vitro and in vivo diagnostic substances2836:Biological products, except diagnostic substances2869:Industrial organic chemicals, nec2899:Chemicals and chemical preparations, nec3841:Surgical and medical instruments and apparatus6719:Offices of holding companies, nec8731:Commercial physical and biological researchTorontoDrugsCanadaBiological products, except diagnostic substances2836FFForeignPublicARI121305001Mnfr pharm,med instrBiotech coCashCash OnlyCommon StockOption633101003Jul 24 20080.000008.60100-11.21500-10.19900-5.40100-3.04000-3.39900-3.059005.643000.515000.00300-11.62900-0.27200-12.19800-11.721002.503000.0150011.64500SFR31 Dec 070.000008622.789000.0000040753.5230067902.80900Swiss Franc31 May 0830 Nov 0730 Nov 0630 Nov 0530 Nov 0430 Nov 031.007001.000002.000003.000004.000005.000006.000007.000008.000009.0000010.0000011.0000012.0000013.0000014.0000015.0000016.0000017.0000018.0000019.0000020.0000021.0000022.0000023.0000024.0000025.0000026.0000027.0000028.0000029.0000030.0000031.0000032.0000033.0000034.0000035.0000036.0000037.0000038.0000039.0000040.0000041.0000042.0000043.0000044.0000045.00000Roche Holding AG,headquartered in Basel,Switzerland, manufacturespharmaceuticals, medicines,diagnostics, chemicals,diagnostic kits, and medicalinstruments. The Group'sprincipal activities are todiscover, develop, manufactureand market novel health caresolutions. The Group operatesthrough two segments namelyPharmaceuticals andDiagnostics. ThePharmaceuticals divisionincludes prescription andmanufacturing ofpharmaceutical products. ThePharmaceutical segment hasthree sub-divisions namelyRoche Prescription, GenentechPrescription and ChugaiPrescription. Diagnosticsegment provides products andservices in all fields ofmedical testing. It alsoprovides reagents and testkits for molecular and cellbiology, analytical systemsand reagents for clinicalchemistry, immunochemistry,hematology and coagulation.Diagnostics division consistsof five business areas:Diabetes Care, Near PatientTesting, CentralizedDiagnostics, MolecularDiagnostics and AppliedScience. It operates inSwitzerland, European Union,United States, North America,Latin America, Japan, Asia,Africa, Australia and Oceania.The company was founded in1896.Roche Holding AG, headquartered in Basel, Switzerland,manufactures pharmaceuticals, medicines, diagnostics,chemicals, diagnostic kits, and medical instruments. TheGroup's principal activities are to discover, develop,manufacture and market novel health care solutions. TheGroup operates through two segments namely Pharmaceuticalsand Diagnostics. The Pharmaceuticals division includesprescription and manufacturing of pharmaceutical products.The Pharmaceutical segment has three sub-divisions namelyRoche Prescription, Genentech Prescription and ChugaiPrescription. Diagnostic segment provides products andservices in all fields of medical testing. It also providesreagents and test kits for molecular and cell biology,analytical systems and reagents for clinical chemistry,immunochemistry, hematology and coagulation. Diagnosticsdivision consists of five business areas: Diabetes Care,Near Patient Testing, Centralized Diagnostics, MolecularDiagnostics and Applied Science. It operates in Switzerland,European Union, United States, North America, Latin America,Japan, Asia, Africa, Australia and Oceania. The company wasfounded in 1896.Roche Holding AG, headquartered in Basel, Switzerland, manufactures pharmaceuticals, medicines, diagnostics, chemicals, diagnostic kits, and medical instruments. The Group's principal activities are to discover, develop, manufacture and market novel health care solutions. The Group operates through two segments namely Pharmaceuticals and Diagnostics. The Pharmaceuticals division includes prescription and manufacturing of pharmaceutical products. The Pharmaceutical segment has three sub-divisions namely Roche Prescription, Genentech Prescription and Chugai Prescription. Diagnostic segment provides products and services in all fields of medical testing. It also provides reagents and test kits for molecular and cell biology, analytical systems and reagents for clinical chemistry, immunochemistry, hematology and coagulation. Diagnostics division consists of five business areas: Diabetes Care, Near Patient Testing, Centralized Diagnostics, Molecular Diagnostics and Applied Science. It operates in Switzerland, European Union, United States, North America, Latin America, Japan, Asia, Africa, Australia and Oceania. The company was founded in 1896.1.000002.000003.000004.000005.000006.000007.000008.000009.00000Arius Research Inc is abiotechnology companyheadquartered in Toronto,Ontario. The company focuseson discovering and developingthe next wave of antibodytherapeutics to treat cancerand other diseases. Thecompany was founded in 1999.Arius Research Inc is a biotechnology company headquarteredin Toronto, Ontario. The company focuses on discovering anddeveloping the next wave of antibody therapeutics to treatcancer and other diseases. The company was founded in 1999.Arius Research Inc is a biotechnology company headquartered in Toronto, Ontario. The company focuses on discovering and developing the next wave of antibody therapeutics to treat cancer and other diseases. The company was founded in 1999.0.000000.000000.0000051.39000YCanadian Dollar23 Jul 08Wed, 23 Jul 2008 00:00:00 ESTDate Announced: 07/23/2008Date Effective:MergerFriendly0.000000.000000.00000-2.165000.000002.44000Price/Share0.00000122.185 Canadian Dollar122.18500122.18500113.657 Canadian Dollar113.657000.000000.000002.422002.42200113.65700113.657 Canadian Dollar0.99300N60.906000.000000.000000.000000.000000.00000121.28700121.28700-10.969000.194000.187000.17900-0.871000.000000.00000100.00000-10.20400-9.8400020.27800-9.3820045.71900-10.57900-10.0850049.149000.000000.000000.000000.000000.000000.000000.000000.000000.000005.643000.0000033.134000.000000.000001.000002.000003.000004.000005.000006.000007.000008.000009.0000010.0000011.0000012.00000CANADA - Roche Holding AGdefinitively agreed to acquireall the outstanding commonstock of Arius Research Inc, abiotechnology company, for2.44 Canadian dollars ($2.422US) in cash per share, or atotal value of C$122.185 mil($121.287 mil). Thetransaction was subject tocustomary closing conditionsand regulatory approvals.CANADA - Roche Holding AG definitively agreed to acquire all the outstanding common stock of Arius Research Inc, a biotechnology company, for 2.44 Canadian dollars ($2.422 US) in cash per share, or a total value of C$122.185 mil ($121.287 mil). The transaction was subject to customary closing conditions and regulatory approvals.CANADA - Roche Holding AG definitively agreed to acquire all the outstanding common stockof Arius Research Inc, a biotechnology company, for 2.44 Canadian dollars ($2.422 US) incash per share, or a total value of C$122.185 mil ($121.287 mil). The transaction wassubject to customary closing conditions and regulatory approvals.CANADA - Roche Holding AG definitively agreed to acquire all the outstanding common stock of Arius Research Inc, a biotechnology company, for 2.44 Canadian dollars ($2.422 US) in cash per share, or atotal value of C$122.185 mil ($121.287 mil). The transaction was subject to customary closing conditions and regulatory approvals.CANADA - Roche Holding AG definitively agreed to acquire all the outstanding common stock of Arius Research Inc, a biotechnology company,for 2.44 Canadian dollars ($2.422 US) in cash per share, or a total value of C$122.185 mil ($121.287 mil). The transaction was subject tocustomary closing conditions and regulatory approvals.$ 112.822 - Merrill Lynch - Adv0.00000Merrill Lynch & Co Inc1.00000Aquilo Partners IncReedland Capital PartnersDundee Securities Corporation1.000002.000003.00000$ 112.822 - Aquilo Partners Inc - Adv$ 112.822 - Reedland Capital Partners - Adv$ 112.822 - Dundee Securities Corporation - Adv0.000000.000000.00000Pending53307.000009761.0000046133.0000076866.000000.11800-11.13900-10.13000-5.36400-3.01900-3.37600-3.038005.60500-11.55000-0.25000-0.18000-0.28000-0.46000-0.37000-0.270005.605008.9820019.19500-0.970001.841002.85900-11.05700-6.44400-2.91400-3.43200-1.82600-12.11500-10.60800-6.44400-3.11400-3.43200-3.09400-11.641001.144002.848000.249000.177000.047002.4860011.5660015.3680023.210001.010003.854003.79000Status:PendingC-9.03700nm0.0000020.6640020.6640.000000.000000.00000114.34500122.117005.64300290.0750041.904000.00000-10.5790021.799002836:Biological products, except diagnostic substances8071:Medical laboratories8731:Commercial physical and biological research8733:Noncommercial research organizations121305001ZurichSwitzerland2834ForeignPublicROG2836:Biological products, except diagnostic substances8071:Medical laboratories8731:Commercial physical and biological research8733:Noncommercial research organizations633101003TorontoCanada2836ForeignPublicARI121.28700113.65700112.8220056.65500Fasken Martineau DuMoulin LLPDeal InformationThomson Financial Mergers & AcquisitionsUS - Roche Holding AG definitively agreed to acquire Mirus Bio Corp, a manufacturer of diagnostic pharmaceuticals, for $### mil. The transaction was subject to customary closing conditions.7/23/2008 11:21:04 AM77119M60484V77119M60484VRoche Holding AGMirus Bio CorpRoche Holding AGMirus Bio Corphttp://www.alacrastore.com/storecontent/Thomson_M%26A/Roche_Holding_AG_acquires_Mirus_Bio_Corp-1997769020sdc/19977690201997769020Copyright © 2008, Thomson Financial, All Rights ReservedZurichDrugsSwitzerlandPharmaceutical preparations2834FFForeignPublicROG2833:Medicinal chemicals and botanical products2834:Pharmaceutical preparations2835:In vitro and in vivo diagnostic substances2836:Biological products, except diagnostic substances2869:Industrial organic chemicals, nec2899:Chemicals and chemical preparations, nec3841:Surgical and medical instruments and apparatus6719:Offices of holding companies, nec8731:Commercial physical and biological research2833:Medicinal chemicals and botanical products2834:Pharmaceutical preparations2835:In vitro and in vivo diagnostic substances2836:Biological products, except diagnostic substances2869:Industrial organic chemicals, nec2899:Chemicals and chemical preparations, nec3841:Surgical and medical instruments and apparatus6719:Offices of holding companies, nec8731:Commercial physical and biological researchDavis Polk & WardwellDrugsUnited StatesIn vitro and in vivo diagnostic substances2835WIWisconsinPrivate121305001Mnfr pharm,med instrMnfr diagnostic pharmaceuticalCashCash OnlyAssets1030132001Jul 23 20080.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000001.000002.000003.000004.000005.000006.000007.000008.000009.0000010.0000011.0000012.0000013.0000014.0000015.0000016.0000017.0000018.0000019.0000020.0000021.0000022.0000023.0000024.0000025.0000026.0000027.0000028.0000029.0000030.0000031.0000032.0000033.0000034.0000035.0000036.0000037.0000038.0000039.0000040.0000041.0000042.0000043.0000044.0000045.00000Roche Holding AG,headquartered in Basel,Switzerland, manufacturespharmaceuticals, medicines,diagnostics, chemicals,diagnostic kits, and medicalinstruments. The Group'sprincipal activities are todiscover, develop, manufactureand market novel health caresolutions. The Group operatesthrough two segments namelyPharmaceuticals andDiagnostics. ThePharmaceuticals divisionincludes prescription andmanufacturing ofpharmaceutical products. ThePharmaceutical segment hasthree sub-divisions namelyRoche Prescription, GenentechPrescription and ChugaiPrescription. Diagnosticsegment provides products andservices in all fields ofmedical testing. It alsoprovides reagents and testkits for molecular and cellbiology, analytical systemsand reagents for clinicalchemistry, immunochemistry,hematology and coagulation.Diagnostics division consistsof five business areas:Diabetes Care, Near PatientTesting, CentralizedDiagnostics, MolecularDiagnostics and AppliedScience. It operates inSwitzerland, European Union,United States, North America,Latin America, Japan, Asia,Africa, Australia and Oceania.The company was founded in1896.Roche Holding AG, headquartered in Basel, Switzerland,manufactures pharmaceuticals, medicines, diagnostics,chemicals, diagnostic kits, and medical instruments. TheGroup's principal activities are to discover, develop,manufacture and market novel health care solutions. TheGroup operates through two segments namely Pharmaceuticalsand Diagnostics. The Pharmaceuticals division includesprescription and manufacturing of pharmaceutical products.The Pharmaceutical segment has three sub-divisions namelyRoche Prescription, Genentech Prescription and ChugaiPrescription. Diagnostic segment provides products andservices in all fields of medical testing. It also providesreagents and test kits for molecular and cell biology,analytical systems and reagents for clinical chemistry,immunochemistry, hematology and coagulation. Diagnosticsdivision consists of five business areas: Diabetes Care,Near Patient Testing, Centralized Diagnostics, MolecularDiagnostics and Applied Science. It operates in Switzerland,European Union, United States, North America, Latin America,Japan, Asia, Africa, Australia and Oceania. The company wasfounded in 1896.Roche Holding AG, headquartered in Basel, Switzerland, manufactures pharmaceuticals, medicines, diagnostics, chemicals, diagnostic kits, and medical instruments. The Group's principal activities are to discover, develop, manufacture and market novel health care solutions. The Group operates through two segments namely Pharmaceuticals and Diagnostics. The Pharmaceuticals division includes prescription and manufacturing of pharmaceutical products. The Pharmaceutical segment has three sub-divisions namely Roche Prescription, Genentech Prescription and Chugai Prescription. Diagnostic segment provides products and services in all fields of medical testing. It also provides reagents and test kits for molecular and cell biology, analytical systems and reagents for clinical chemistry, immunochemistry, hematology and coagulation. Diagnostics division consists of five business areas: Diabetes Care, Near Patient Testing, Centralized Diagnostics, Molecular Diagnostics and Applied Science. It operates in Switzerland, European Union, United States, North America, Latin America, Japan, Asia, Africa, Australia and Oceania. The company was founded in 1896.1.000002.000003.000004.00000Mirus Bio Corp, manufacturerof diagnostic pharmaceuticals,headquartered in Madison,Wisconsin.Mirus Bio Corp, manufacturer of diagnostic pharmaceuticals,headquartered in Madison, Wisconsin.Mirus Bio Corp, manufacturer of diagnostic pharmaceuticals, headquartered in Madison, Wisconsin.0.000000.000000.000000.00000YU.S. Dollar22 Jul 08Tue, 22 Jul 2008 00:00:00 ESTDate Announced: 07/22/2008Date Effective:Acq. of AssetsFriendly0.000000.000000.000000.000000.000000.00000Price/Share0.00000125 U.S. Dollar125.000000.00000125 U.S. Dollar125.000000.000000.000000.000000.00000125.00000125 U.S. Dollar1.00000N62.770000.000000.000000.000000.000000.00000125.00000125.000000.000000.000000.000000.000000.000000.000000.00000100.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000001.000002.000003.000004.000005.000006.000007.00000US - Roche Holding AGdefinitively agreed to acquireMirus Bio Corp, a manufacturerof diagnostic pharmaceuticals,for $125 mil. The transactionwas subject to customaryclosing conditions.US - Roche Holding AG definitively agreed to acquire Mirus Bio Corp, a manufacturer of diagnostic pharmaceuticals, for $125 mil. The transaction was subject to customary closing conditions.US - Roche Holding AG definitively agreed to acquire Mirus Bio Corp, a manufacturer ofdiagnostic pharmaceuticals, for $125 mil. The transaction was subject to customary closingconditions.US - Roche Holding AG definitively agreed to acquire Mirus Bio Corp, a manufacturer of diagnostic pharmaceuticals, for $125 mil. The transaction was subject to customary closing conditions.US - Roche Holding AG definitively agreed to acquire Mirus Bio Corp, a manufacturer of diagnostic pharmaceuticals, for $125 mil. Thetransaction was subject to customary closing conditions.Pending0.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.00000Status:Pending-999.00000np0.00000-999.00000np0.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000002833:Medicinal chemicals and botanical products2834:Pharmaceutical preparations2835:In vitro and in vivo diagnostic substances121305001ZurichSwitzerland2834ForeignPublicROG2833:Medicinal chemicals and botanical products2834:Pharmaceutical preparations2835:In vitro and in vivo diagnostic substances1030132001United States2835WisconsinPrivate125.00000125.00000125.0000062.77000Deal InformationThomson Financial Mergers & Acquisitionshttp://www.alacrastore.com/storecontent/fitch/426907_pr_framefitch/426907_pr_framehtmlFitch Ratings is a leading global rating agency committed to providing the world's credit markets with independent, timely and prospective credit opinions. Built on a foundation of organic growth and strategic acquisitions, Fitch Ratings has grown rapidly during the past decade gaining market presence throughout the world and across all fixed income markets.Roche Holding Ltd.825886837/23/2008 10:14:54 AM01030000010317000103170385Press ReleaseRO426907_pr_frameCredit & Investment ResearchFitchResearchhttp://www.alacrastore.com/storecontent/fitch/426884_pr_framefitch/426884_pr_framehtmlFitch Ratings is a leading global rating agency committed to providing the world's credit markets with independent, timely and prospective credit opinions. Built on a foundation of organic growth and strategic acquisitions, Fitch Ratings has grown rapidly during the past decade gaining market presence throughout the world and across all fixed income markets.Roche Deutschland Holding GmbHRoche Holding Ltd.80457983825886837/23/2008 10:14:53 AM01030000010317000103170385Press ReleaseRO426884_pr_frameCredit & Investment ResearchFitchResearchUS - Roche Holding AG planned to launch an unsolicited tender offer to acquire the remaining ##.#% stake, or ###.### mil common shares, which it did not already own, in Genentech Inc, a biotechnology company, for $## in cash per share, or a total value of $##.### bil. The transaction was subject to customary closing conditions and shareholder approval.7/22/2008 6:51:14 PM77119M36871077119M77119MRoche Holding AGGenentech IncRoche Holding AGRoche Holding AGhttp://www.alacrastore.com/storecontent/Thomson_M%26A/Roche_Holding_AG_intends_to_purchase_remaining_interest_in_Genentech_Inc-1997172020sdc/19971720201997172020Copyright © 2008, Thomson Financial, All Rights ReservedZurichDrugsSwitzerlandPharmaceutical preparations2834FFForeignPublicROG2833:Medicinal chemicals and botanical products2834:Pharmaceutical preparations2835:In vitro and in vivo diagnostic substances2836:Biological products, except diagnostic substances2869:Industrial organic chemicals, nec2899:Chemicals and chemical preparations, nec3841:Surgical and medical instruments and apparatus6719:Offices of holding companies, nec8731:Commercial physical and biological research2833:Medicinal chemicals and botanical products2834:Pharmaceutical preparations2835:In vitro and in vivo diagnostic substances2836:Biological products, except diagnostic substances2869:Industrial organic chemicals, nec2899:Chemicals and chemical preparations, nec3841:Surgical and medical instruments and apparatus6719:Offices of holding companies, nec8731:Commercial physical and biological researchDavis Polk & WardwellNew YorkDrugsUnited StatesBiological products, except diagnostic substances2836CACaliforniaPublicDNA121305001Mnfr pharm,med instrMnfr pharm,med instrCashCash OnlyCommon Stock2513006Jul 22 20080.000004505.000000.000004731.000003613.000002410.791001545.727000.0000013285.000000.305000.186005078.000002.880003080.000005011.0000012176.000000.0000019119.00000SFR31 Dec 070.0000011.360008622.789000.0000040753.5230067902.80900Swiss Franc30 Jun 0831 Dec 0731 Dec 0631 Dec 0531 Dec 0431 Dec 031.000001.000002.000003.000004.000005.000006.000007.000008.000009.0000010.0000011.0000012.0000013.0000014.0000015.0000016.0000017.0000018.0000019.0000020.0000021.0000022.0000023.0000024.0000025.0000026.0000027.0000028.0000029.0000030.0000031.0000032.0000033.0000034.0000035.0000036.0000037.0000038.0000039.0000040.0000041.0000042.0000043.0000044.0000045.00000Roche Holding AG,headquartered in Basel,Switzerland, manufacturespharmaceuticals, medicines,diagnostics, chemicals,diagnostic kits, and medicalinstruments. The Group'sprincipal activities are todiscover, develop, manufactureand market novel health caresolutions. The Group operatesthrough two segments namelyPharmaceuticals andDiagnostics. ThePharmaceuticals divisionincludes prescription andmanufacturing ofpharmaceutical products. ThePharmaceutical segment hasthree sub-divisions namelyRoche Prescription, GenentechPrescription and ChugaiPrescription. Diagnosticsegment provides products andservices in all fields ofmedical testing. It alsoprovides reagents and testkits for molecular and cellbiology, analytical systemsand reagents for clinicalchemistry, immunochemistry,hematology and coagulation.Diagnostics division consistsof five business areas:Diabetes Care, Near PatientTesting, CentralizedDiagnostics, MolecularDiagnostics and AppliedScience. It operates inSwitzerland, European Union,United States, North America,Latin America, Japan, Asia,Africa, Australia and Oceania.The company was founded in1896.Roche Holding AG, headquartered in Basel, Switzerland,manufactures pharmaceuticals, medicines, diagnostics,chemicals, diagnostic kits, and medical instruments. TheGroup's principal activities are to discover, develop,manufacture and market novel health care solutions. TheGroup operates through two segments namely Pharmaceuticalsand Diagnostics. The Pharmaceuticals division includesprescription and manufacturing of pharmaceutical products.The Pharmaceutical segment has three sub-divisions namelyRoche Prescription, Genentech Prescription and ChugaiPrescription. Diagnostic segment provides products andservices in all fields of medical testing. It also providesreagents and test kits for molecular and cell biology,analytical systems and reagents for clinical chemistry,immunochemistry, hematology and coagulation. Diagnosticsdivision consists of five business areas: Diabetes Care,Near Patient Testing, Centralized Diagnostics, MolecularDiagnostics and Applied Science. It operates in Switzerland,European Union, United States, North America, Latin America,Japan, Asia, Africa, Australia and Oceania. The company wasfounded in 1896.Roche Holding AG, headquartered in Basel, Switzerland, manufactures pharmaceuticals, medicines, diagnostics, chemicals, diagnostic kits, and medical instruments. The Group's principal activities are to discover, develop, manufacture and market novel health care solutions. The Group operates through two segments namely Pharmaceuticals and Diagnostics. The Pharmaceuticals division includes prescription and manufacturing of pharmaceutical products. The Pharmaceutical segment has three sub-divisions namely Roche Prescription, Genentech Prescription and Chugai Prescription. Diagnostic segment provides products and services in all fields of medical testing. It also provides reagents and test kits for molecular and cell biology, analytical systems and reagents for clinical chemistry, immunochemistry, hematology and coagulation. Diagnostics division consists of five business areas: Diabetes Care, Near Patient Testing, Centralized Diagnostics, Molecular Diagnostics and Applied Science. It operates in Switzerland, European Union, United States, North America, Latin America, Japan, Asia, Africa, Australia and Oceania. The company was founded in 1896.1.000002.000003.000004.000005.000006.000007.000008.000009.0000010.0000011.0000012.0000013.0000014.0000015.0000016.0000017.0000018.0000019.0000020.0000021.0000022.0000023.0000024.0000025.0000026.00000Genentech Inc, located inSouth San Francisco,California, is a biotechnologycompany that discovers,develops, manufactures andcommercializesbiotherapeutics. It marketsAvastin for treatingmetastatic cancer of the colonor rectum and metastaticnon-squamous non-small celllung cancer. The Company alsocommercialized Rituxan totreat B-cell non-Hodgkin'slymphoma, Herceptin fortreating node-positive breastcancer, Lucentis to treatneovascular age-relatedmacular degeneration, Xolairfor adults with asthma,Tarceva for the treatment ofmetastatic non-small cell lungcancer and Nutropin andNutropin AQ growth hormoneproducts. The company wasfounded in 1976.Genentech Inc, located in South San Francisco, California,is a biotechnology company that discovers, develops,manufactures and commercializes biotherapeutics. It marketsAvastin for treating metastatic cancer of the colon orrectum and metastatic non-squamous non-small cell lungcancer. The Company also commercialized Rituxan to treatB-cell non-Hodgkin's lymphoma, Herceptin for treatingnode-positive breast cancer, Lucentis to treat neovascularage-related macular degeneration, Xolair for adults withasthma, Tarceva for the treatment of metastatic non-smallcell lung cancer and Nutropin and Nutropin AQ growth hormoneproducts. The company was founded in 1976.Genentech Inc, located in South San Francisco, California, is a biotechnology company that discovers, develops, manufactures and commercializes biotherapeutics. It markets Avastin for treating metastatic cancer of the colon or rectum and metastatic non-squamous non-small cell lung cancer. The Company also commercialized Rituxan to treat B-cell non-Hodgkin's lymphoma, Herceptin for treating node-positive breast cancer, Lucentis to treat neovascular age-related macular degeneration, Xolair for adults with asthma, Tarceva for the treatment of metastatic non-small cell lung cancer and Nutropin and Nutropin AQ growth hormone products. The company was founded in 1976.0.000000.000000.000001050.89000YU.S. Dollar21 Jul 08Mon, 21 Jul 2008 00:00:00 ESTDate Announced: 07/21/2008Date Effective:Acq. Rem. Int.Unsolic.0.000000.000000.00000-2030.000000.0000089.00000Price/Share0.0000041246.5 U.S. Dollar41246.4520093529.3690041246.5 U.S. Dollar41246.452000.000000.0000089.0000089.0000039216.4520041246.5 U.S. Dollar1.00000N20593.365000.000000.000000.000000.000000.0000041246.4520041246.452000.000000.00000-0.40000-0.65900-0.167005.8680055.9000044.100000.0000018.419007.0400030.367007.681008.6100030.367007.68100116544.6630081.8200075.3900074.1800040.087000.000000.157000.0000048.152000.000002475.0000077955.1520013285.0000026.246000.0000047.139000.0000019.980008.7800018.050001.000002.000003.000004.000005.000006.000007.000008.000009.0000010.0000011.0000012.0000013.00000US - Roche Holding AG plannedto launch an unsolicitedtender offer to acquire theremaining 44.1% stake, or463.443 mil common shares,which it did not already own,in Genentech Inc, abiotechnology company, for $89in cash per share, or a totalvalue of $41.246 bil. Thetransaction was subject tocustomary closing conditionsand shareholder approval.US - Roche Holding AG planned to launch an unsolicited tender offer to acquire the remaining 44.1% stake, or 463.443 mil common shares, which it did not already own, in Genentech Inc, a biotechnology company, for $89 in cash per share, or a total value of $41.246 bil. The transaction was subject to customary closing conditions and shareholder approval.US - Roche Holding AG planned to launch an unsolicited tender offer to acquire theremaining 44.1% stake, or 463.443 mil common shares, which it did not already own, inGenentech Inc, a biotechnology company, for $89 in cash per share, or a total value of$41.246 bil. The transaction was subject to customary closing conditions and shareholderapproval.US - Roche Holding AG planned to launch an unsolicited tender offer to acquire the remaining 44.1% stake, or 463.443 mil common shares, which it did not already own, in Genentech Inc, a biotechnologycompany, for $89 in cash per share, or a total value of $41.246 bil. The transaction was subject to customary closing conditions and shareholder approval.US - Roche Holding AG planned to launch an unsolicited tender offer to acquire the remaining 44.1% stake, or 463.443 mil common shares,which it did not already own, in Genentech Inc, a biotechnology company, for $89 in cash per share, or a total value of $41.246 bil. Thetransaction was subject to customary closing conditions and shareholder approval.$ 41,246.452 - Greenhill & Co, LLC - Adv0.00000Greenhill & Co, LLC1.00000Intended53307.000009761.0000046133.0000076866.0000012.642000.000004731.000003613.000002410.791001545.727000.0000013285.000005078.000002.590000.000001.180000.730000.000002.8800013285.0000011905.000000.000007469.584006782.190000.000002769.000002113.000001278.99100784.816000.000003080.000004426.000003403.000002012.849001219.416000.000005011.0000011724.000009284.000006633.372004621.157000.0000012176.0000019119.0000018940.000000.0000012000.969009383.054000.00000Status:IntendedUS30.9030030.9030.412007.040007.04048.286000.0000023.1840032.945000.0000013285.0000025.627000.000000.0000018.419007.040002836:Biological products, except diagnostic substances8071:Medical laboratories8731:Commercial physical and biological research8733:Noncommercial research organizations121305001ZurichSwitzerland2834ForeignPublicROG2833:Medicinal chemicals and botanical products2834:Pharmaceutical preparations2835:In vitro and in vivo diagnostic substances2836:Biological products, except diagnostic substances2869:Industrial organic chemicals, nec2899:Chemicals and chemical preparations, nec3841:Surgical and medical instruments and apparatus6719:Offices of holding companies, nec8731:Commercial physical and biological research121305001ZurichSwitzerland2834ForeignPublicROG41246.4520041246.4520041246.4520020593.36500Deal InformationThomson Financial Mergers & Acquisitionshttp://www.alacrastore.com/storecontent/moodys/PR_159619_600035606moodys/PR_159619_600035606htmlGlobal Credit Research Rating Action ## JUL #### Rating Action: Roche Holding AG Moody's reviews Roche's Aa# rating for possible downgrade; affirms P-# Paris, July ##, #### -- Moody's Investors Service has today placed the Aa# long-term...7/22/2008 12:28:07 AMhtmlRoche Holding AGRoche Holding AG600035606150.0000NewsRating ActionPR_159619_600035606Credit & Investment ResearchMoody's Global Credit Researchhttp://www.alacrastore.com/storecontent/spcred/660667spcred/660667normThe latest News from S&Pglobal7/21/2008 3:33:00 PM100News660667SwitzerlandPharmaceuticalsEurope, Middle East, AfricaGlobal IssuersCorporationsHealth CareConsumer ProductsNewsFRANKFURT (Standard&Poor's) July 21, 2008--Standard&Poor's Ratings Services today lowered its long-term corporate credit rating on Switzerland-based pharmaceuticals and diagnostics group Roche Holding AG (Roche) to 'AA–' from 'AA+'. This action follows the announcement by Roche of its debt-financed plan to acquire the outstanding publicly held minority interest of its 56%-owned subsidiary, U.S.-based biopharmaceuticals company Genentech Inc., for a total payment of approximately $43.7 billion. The outlook is stable. At the same time, Standard&Poor's lowered its long-term corporate credit rating on Genentech Inc. to 'AA-' from 'AA', to reflect the rating on the parent company. In addition, the 'A-1+' short-term rating on both Roche and Genentech was affirmed. The outlook on Genentech is stable. The 'AA-'CHE35202010 352020 3520 35Roche Holding AG395852EUROMIDAFRROG@VXNEWSGLOBISSCORPHealthConsumerCredit & Investment ResearchS&P Credit Researchhttp://www.alacrastore.com/storecontent/spcred/660668spcred/660668normThe latest Research Update from S&Pglobalstructured7/21/2008 3:33:00 PM175Research Update660668SwitzerlandPharmaceuticalsEurope, Middle East, AfricaStructured FinanceGlobal IssuersAsset-Backed SecuritiesFinancial InstitutionsCorporationsHealth CareConsumer ProductsResearch UpdateOn July 21, 2008, Standard&Poor's Ratings Services lowered its long-term corporate credit rating on Switzerland-based pharmaceuticals and diagnostics group Roche Holding AG (Roche) to 'AA–' from 'AA+'. This action follows the announcement by Roche of its debt-financed plan to acquire the outstanding publicly held minority interest of its 56%-owned subsidiary, U.S.-based biopharmaceuticals company Genentech Inc., for a total payment of approximately $43.7 billion. The outlook is stable. At the same time, Standard&Poor's lowered its long-term corporate credit rating on Genentech Inc. to 'AA-' from 'AA', to reflect the rating on the parent company. In addition, the 'A-1+' short-term rating on both Roche and Genentech was affirmed. The outlook on Genentech is stable. The 'AA-' ratings onCHE35202010 352020 3520 35Roche Holding AG395852EUROMIDAFRROG@VXRESUPDUSA36871035201010 352010 3520 35Genentech Inc.347136USADNASTRUCGLOBISSABSFICORPHealthConsumerCredit & Investment ResearchS&P Credit ResearchUS - Fontus Pharmaceuticals Inc acquired the ROCALTROL brand of Roche Laboratories Inc, a manufacturer of pharmaceuticals and a unit of Roche Holding AG's Hoffmann-La Roche Inc subsidiary.6/18/2008 2:50:14 PM34493M77115L34493M77119MFontus Pharmaceuticals IncRoche Laboratories Inc- ROCALTROL BrandFontus Pharmaceuticals IncRoche Holding AGhttp://www.alacrastore.com/storecontent/Thomson_M%26A/Fontus_Pharmaceuticals_Inc_acquires_Roche_Labs_ROCALTROL_Brand_from_Roche_Holding_AG-1987415020sdc/19874150201987415020Copyright © 2008, Thomson Financial, All Rights ReservedDrugsUnited StatesPharmaceutical preparations2834NJNew JerseyPrivate2833:Medicinal chemicals and botanical products2834:Pharmaceutical preparations2836:Biological products, except diagnostic substances2833:Medicinal chemicals and botanical products2834:Pharmaceutical preparations2836:Biological products, except diagnostic substancesDrugsUnited StatesPharmaceutical preparations2834NJNew JerseySubsidiary1023104001Pharm coMnfr pharm,med instrUnspecifiedAssets1023108001Jun 18 20080.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000001.000002.000003.000004.000005.000006.000007.000008.000009.0000010.0000011.0000012.00000Fontus Pharmaceuticals Inc isa pharmaceutical company,headquartered in Parsippany,New Jersey, and with otherlocation in New York. Thecompany acquires and marketsFDA-approved products innephrology, endocrinology andacute care, areas withsignificant unmet medicalneed. The company was foundedin 2007.Fontus Pharmaceuticals Inc is a pharmaceutical company,headquartered in Parsippany, New Jersey, and with otherlocation in New York. The company acquires and marketsFDA-approved products in nephrology, endocrinology and acutecare, areas with significant unmet medical need. The companywas founded in 2007.Fontus Pharmaceuticals Inc is a pharmaceutical company, headquartered in Parsippany, New Jersey, and with other location in New York. The company acquires and markets FDA-approved products in nephrology, endocrinology and acute care, areas with significant unmet medical need. The company was founded in 2007.1.000002.000003.00000The assets comprised of theROCALTROL brand of RocheLaboratories Inc.The assets comprised of the ROCALTROL brand of RocheLaboratories Inc.The assets comprised of the ROCALTROL brand of Roche Laboratories Inc.0.000000.000000.000000.00000N16 Jun 08Mon, 16 Jun 2008 00:00:00 ESTDate Announced: 06/16/200816 Jun 08Date Effective: 06/16/200816 Jun 08Acq. of AssetsFriendly0.000000.000000.000000.000000.000000.00000Price/Share0.0000000.000000.0000000.00000100.00000100.000000.000000.000000.0000000.00000N0.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.00000100.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000001.000002.000003.000004.000005.000006.000007.00000US - Fontus PharmaceuticalsInc acquired the ROCALTROLbrand of Roche LaboratoriesInc, a manufacturer ofpharmaceuticals and a unit ofRoche Holding AG's Hoffmann-LaRoche Inc subsidiary.US - Fontus Pharmaceuticals Inc acquired the ROCALTROL brand of Roche Laboratories Inc, a manufacturer of pharmaceuticals and a unit of Roche Holding AG's Hoffmann-La Roche Inc subsidiary.US - Fontus Pharmaceuticals Inc acquired the ROCALTROL brand of Roche Laboratories Inc, amanufacturer of pharmaceuticals and a unit of Roche Holding AG's Hoffmann-La Roche Incsubsidiary.US - Fontus Pharmaceuticals Inc acquired the ROCALTROL brand of Roche Laboratories Inc, a manufacturer of pharmaceuticals and a unit of Roche Holding AG's Hoffmann-La Roche Inc subsidiary.US - Fontus Pharmaceuticals Inc acquired the ROCALTROL brand of Roche Laboratories Inc, a manufacturer of pharmaceuticals and a unit ofRoche Holding AG's Hoffmann-La Roche Inc subsidiary.Completed0.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.00000Status:Completed-999.00000np0.00000-999.00000np0.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000002833:Medicinal chemicals and botanical products2834:Pharmaceutical preparations2836:Biological products, except diagnostic substances1023104001United States2834New JerseyPrivate2833:Medicinal chemicals and botanical products2834:Pharmaceutical preparations2835:In vitro and in vivo diagnostic substances2836:Biological products, except diagnostic substances2869:Industrial organic chemicals, nec2899:Chemicals and chemical preparations, nec3841:Surgical and medical instruments and apparatus6719:Offices of holding companies, nec8731:Commercial physical and biological research121305001ZurichSwitzerland2834ForeignPublicROG0.000000.000000.000000.00000Deal InformationThomson Financial Mergers & AcquisitionsJAPAN - Roche Pharmholding BV, a wholly-owned unit of Roche Finance Ltd, a wholly-owned unit of Roche Holding AG, launched a tender offer to raise stake to ##.##% from ##.##%, by acquiring a ##.##% stake, or ##.### mil ordinary shares, in Chugai Pharmaceutical Co Ltd, a manufacturer of pharmaceuticals, for #,### Japanese yen ($##.### US) in cash per share, or a total value of ##.### bil yen ($###.### mil).5/25/2008 12:30:42 AM77123N17126877119M77119MRoche Pharmholding BVChugai Pharmaceutical Co LtdRoche Holding AG